Leveraging preclinical animal data for a phase I first-in-man trial is appealing yet challenging. A prior based on animal data may place large probability mass on values of the dose-toxicity model parameter(s), which appear infeasible in light of data accrued from the ongoing phase I clinical trial. In this paper, we seek to use animal data to improve decision making in a model-based dose-escalation procedure for phase I oncology trials. Specifically, animal data are incorporated via a robust mixture prior for the parameters of the dose-toxicity relationship. This prior changes dynamically as the trial progresses. After completion of treatment for each cohort, the weight allocated to the informative component, obtained based on animal data alone, is updated using a decision-theoretic approach to assess the commensurability of the animal data with the human toxicity data observed thus far. In particular, we measure commensurability as a function of the utility of optimal prior predictions for the human responses (toxicity or no toxicity) on each administered dose. The proposed methodology is illustrated through several examples and an extensive simulation study. Results show that our proposal can address difficulties in coping with prior-data conflict commencing in sequential trials with a small sample size.
Introduction
Phase I oncology trials are performed primarily to characterise the toxicity profile of an anticancer therapy in human subjects. Regulatory authorities require that first-in-man trials be preceded by non-clinical safety studies in at least two animal species, including the most sensitive and relevant species [1, 2] . It is therefore reasonable to assume that some animal data will be available at the time of designing a phase I clinical trial. Despite this availability, trialists may be uncertain about how and whether to leverage animal data. On the one hand, there is considerable motivation to design and conduct more efficient phase I clinical trials, basing interim dose-escalation decisions on relevant information internal and external to the trial [3, 4] . On the other hand, leveraging animal data could risk patient safety [5, 6, 7] , if it emerges that parameters of the human dose-toxicity relationship, predicted from animal data, are non-exchangeable with the parameters of the true (but unknown) human relationship. In this paper, we propose a quantitative approach for leveraging preclinical animal data for the design and interpretation of a phase I first-in-man trial.
There exists Bayesian and frequentist approaches for incorporating historical data into the analysis of a new clinical trial [8] . This paper will focus on Bayesian approaches for leveraging historical, or more generally, complementary (co-)data [4] , comprising all relevant historical and concurrent data into a new study. Proposals include power priors [9, 10, 11] , commensurate priors [12, 13] and robust meta-analytic predictive priors [14, 15] . Power priors are so-called because this approach raises the likelihood of the co-data to a power weight between 0 and 1. This exponent can be treated as a constant and could be fixed in advance on the basis of our prior scientific understanding of the similarity of parameters underpinning the distributions of the co-data and the new data. Alternatively, Gravestock and Held [16] adopt an adaptive versions of the power prior, which estimate the power using an empirical Bayes approach, and fix the power equal to the estimate maximising the marginal likelihood of the historical and new data. The normalised power prioradopt an empirical Bayes approach, and fix the power equal to the estimate maximising the marginal likelihood of the historical and new data. The normalised power prior [10] treats the exponent as a random variable, with a prior distribution which is updated once the new data are observed. A prior-data conflict will result in a posterior placing probability mass on powers close to 0, thus down-weighting the contribution of the co-data to the posterior of the parameter of interest.
Other examples of Bayesian dynamic priors, where the degree of down-weighting reacts to the similarity of the observed and historical data include commensurate priors and meta-analytic predictive priors. Commensurate priors [12] stipulate a conditional prior for the parameter underpinning the distribution of the new trial data, which is centred at the historical data parameter and has precision parameter for capturing the commensurability of the co-data and new trial data. Hobbs et al. [13] present empirical and fully Bayesian modifications of the commensurate prior to general and generalised linear models. Metaanalytic approaches leveraging co-data assume that parameters underpinning the historical trials and the new trial are exchangeable, that is, are conditionally independent draws from a distribution, for example, a normal distribution with unknown mean µ and variance τ 2 . Here τ captures the degree of heterogeneity between parameters underpinning different trials, with larger values leading to greater attenuation of the co-data. To encourage faster discounting of the historical data when there is a prior-data conflict, Schmidli et al. [15] develop a robust heavy-tailed prior [17] , which is a two-component mixture distribution with one component the meta-analytic predictive prior and the other a weakly-informative (proper) distribution. Mutsvari et al. [18] discuss how to stipulate this weakly informative component for a robust inference.
Application of these methods has mainly been found in phase II clinical trials for borrowing of information from a historical control to the concurrent control. In general, incorporating historical control data would result in benefits such as increasing power and potentially reducing the sample size when a discrepancy between historical and concurrent control is small [19, 20] . However, very little has been written on leveraging historical data, particularly the preclinical animal data, into phase I dose-escalation studies, where metrics for assessing the benefits of borrowing towards the trial operating characteristics are very different from those appropriate in the context of phase II clinical trials for efficacy. Zheng et al. [21] propose a robust Bayesian hierarchical random-effects model to incorporate data from multiple studies performed in one or more animal species into the analysis of a phase I oncology trial. The dose-toxicity relationship learned from animal data is projected onto an equivalent human dosing scale, using a translation parameter formulated from allometric scaling. A log-normal prior, appropriate for each species, is specified for the translation parameter to describe uncertainty about the magnitude of differences in toxicity between animals and humans. This then leads to a feasible assumption that the standardised animal parameters are exchangeable with the human parameters of the logistic dose-toxicity model. Possibility of non-exchangeability of parameters is also considered. The robust Bayesian hierarchical model is best fitted with animal data collected from several studies that have evaluated a number of doses.
In this paper, we represent preclinical animal data in a bivariate normal prior for the parameters of the human dose-toxicity relationship, assuming this can be adequately described by a two-parameter logistic regression model [22, 23] . We analyse the accumulating human data on dose-limiting toxicities (DLTs) using a mixture prior that comprises (i) an informative component based on the animal data and (ii) a weakly informative prior. We use empirical mixture weights, which are updated at each interim analysis of the adaptive Bayesian dose-escalation trial by comparing the human data observed thus far with what we would expect based on the animal data. Decision-making in our context about incorporating animal data or not seems to be an ideal setup to apply the Bayesian decision theory, which has been widely considered in early phase clinical trials to quantify the trade-off between various decisions using probabilities and costs [24] . Stallard and Thall [25] develop a decision-theoretic approach to the selection of candidate treatments prior to a phase II oncology trial. Hee and Stallard [26] discuss a kind of sequential design, wherein a series of phase II trials and a phase III trial are conducted in a row, relating the decision of continuing recruitment or termination with the consequences in long-term. Articles using Bayesian decision theory to make phase I trials more ethical include Whitehead and Brunier [27] , Whitehead and Williamson [22] , and Whitehead et al. [28] .
In our problem, incorporating different types of animal data, which may over-or under-predict the toxicity in humans, will result in very different dose recommendations for patients who will enter the trial at later stages. We thus propose using Bayesian decision theory to measure the commensurability of the animal and human data, so as to update the empirical mixture weight along as the trial progresses. Adapting the idea of Fouskakis and Draper [29] , we assess the commensurability using the discrepancy between predicted human toxicity, based on the animal data, with observed human responses. More specifically, before patients of a new cohort is treated, animal data are used to derive optimal prior predictions for the human DLT outcomes at the dose recommended. Predictions are optimal in the sense that they have maximum expected utility, where utilities are defined as dimensionless quantities between 0 and 1, with higher utilities assigned to correct predictions and vice versa. Once the human DLT outcomes from the latest cohort are observed, commensurability of the human and animal data is measured by the attained utility (which we will refer to as predictive utility) of the predictions, averaging across relevant doses used thus far in the trial. This measure of commensurability determines the weight assigned to the informative component of the mixture prior (based on the animal data) that is used to analyse the data accrued thus far and deduce the dose recommendation for the next patient cohort.
The remainder of the paper is structured as follows. Starting with a motivating example in Section 2, we explain in Section 3 how preclinical data from a single animal species on two or more doses can be represented in a bivariate normal prior for the dose-toxicity parameters of the human trial. In Section 4, we propose a Bayesian decision-theoretic approach to adaptively leverage animal data according to a formal assessment of commensurability. We then retrospectively design and analyse the example trial applying the proposed methodology in section 5, and describe a simulation study performed to evaluate the operating characteristics of a Bayesian phase I dose-escalation study in Section 6. We close with a discussion of our findings and future research interest in Section 7.
Motivating example
Sessa et al. [30] report a phase I first-in-man trial intended to estimate the maximum tolerated dose (MTD) of the anticancer therapy AUY922. The trial enrolled 101 patients who were treated sequentially in cohorts of size three or more. Patients were monitored to record whether or not they experienced a dose-limiting toxicity (DLT). Nine doses were evaluated during the study, summarised by the dosing set D = {2, 4, 8, 16, 22, 28, 40, 54 , 70} mg/m 2 . Dose-escalation decisions were guided by a two-parameter Bayesian logistic regression model (BLRM) for the relationship between dose and DLT risk [23] . The model was implemented placing weakly informative priors on the model parameters consistent with median DLT probabilities of around 0.1% and 33% at doses 2 and 28 mg/m 2 , respectively; these settings were informed by data from toxicology studies performed in dogs [30] , although the animal data were not formally incorporated into the analysis of the phase I trial. Let p i denote the DLT risk on the ith largest dose in D, d i , and let x (h−1) H be a vector of observed outcomes from the first (h − 1) cohorts of patients. Then the BLRM procedure recommends that the cohort h receives dose d (h) sel , defined as the highest dose in D with an acceptable risk of excessive toxicity:
Sessa et al. [30] implemented the BLRM-guided escalation procedure with the additional constraint that d
sel should not exceed more than a two-fold increase in the current dose.
The AUY922 phase I clinical trial prompts the following questions:
(i) How can we formally incorporate preclinical data into prior distributions for the dose-toxicity model parameters?
(ii) How can we dynamically update these priors in response to the observed prior-data conflicts, particularly when few data are available, as is often the case in a phase I trial?
These questions will motivate the methodology developed in Sections 3 and 4. In what follows, we will define the MTD as the dose associated with a target DLT risk of Γ.
3 Representing animal data in a prior for dose-toxicity parameters
In this section, we outline our approach for leveraging animal data in a phase I dose-escalation study. Let
I} contain all doses available for evaluation. Furthermore, let n i denote the number of patients treated with dose d i , of whom r i experience a DLT. Several authors [21, 22, 23] have used a two-parameter BLRM to inform dose escalation decisions in a phase I trial. We follow these authors to assume that DLT risk increases monotonically with dose and that this relationship can be described as:
where d Ref is a pre-defined reference dose drawn from D and θ 1 is the log-odds of toxicity on d Ref .
In what follows, we are interested in estimating the dose-toxicity parameter vector θ = (θ 1 , θ 2 ).
Suppose that when planning the first-in-man trial, data are available from one preclinical study performed in a single animal species thought to be relevant for predicting DLT risks in humans. At a minimum, data must be available on at least two doses and at least one toxicity must have been observed on the highest dose. For ease of explanation, we now proceed assuming we have preclinical data on two doses. Indexing animal doses by j = 0, −1, if t Aj animals out of a total of (t Aj + ν Aj ) administered dose d Aj experienced a toxicity, we can represent the animal data by x A = {(d Aj , t Aj , v Aj ); j = −1, 0}. We follow Zheng et al. [21] and use allometric scaling on the basis of body surface area [1, 31] to translate the animal dose-toxicity curve onto an equivalent human dosing scale, assuming differences in DLT risk between an animal species and humans, given the same dose, can be largely explained by differences in size. In this way, we can identify doses d −1 and d 0 such that, for j = 0, −1, the risk of a DLT in humans given dose d j is anticipated to be similar to the risk of a DLT in animals given dose d Aj . Doses d −1 and d 0 are not necessarily contained in D. For j = −1, 0, we stipulate an independent prior p j ∼ Beta(t Aj , v Aj ) for the DLT risk in humans given dose d j , which has effective sample size (ESS) equal to (t Aj + v Aj ) [32] . Thus, the translated preclinical data on animal dose d Aj are taken to represent observations on (t Aj +v Aj ) patients on dose d j .
Using these independent Beta priors for p −1 and p 0 , and assuming the dose-toxicity relationship follows Model (2), we can apply a Jacobian transformation to obtain the joint prior probability density function (pdf) of θ 2 and p i , for 1 ≤ i ≤ I, as:
where
The marginal prior pdf of p i is given by
and the prior cumulative distribution function (cdf) for p i evaluated at p i = p is
We outline below how we can represent the preclinical information on toxicity probabilities, p 1 , . . . , p I , by a bivariate normal prior for θ, the vector of dose-toxicity parameters. The general idea of finding an approximate prior for θ by matching percentiles of the marginal priors for p 1 , . . . , p I is due to Neuenschwander et al. [23] .
(i) For each i = 1, . . . , I, summarise the prior for p i defined by cdf (5) by K percentiles. We recommend using three (or more) percentiles. In our illustrative examples, we find the median, together with the 2.5th and 97.5th percentiles. The (100t ik )th percentile, denoted by q(t ik ), is found as the solution to:
For ease of presentation, we will write q ik = q(t ik ).
(ii) We stipulate θ ∼ BVN(µ, Σ). We then use a modified quasi-Newton algorithm [33] , with constraints set to the correlation of θ 1 and θ 2 , to search over configurations of µ and Σ to find the one minimising the total absolute distance between percentiles of the fitted marginal priors for the p i , denoted by q 11 , . . . , q 1K , . . . , q I1 , . . . , q IK , and the orginal percentiles calculated in step (i). This distance measure is formally defined as:
Hereafter, we denote the pdf of the bivariate normal prior for θ as π 0 (θ|x A ). The above approach for deriving π 0 (θ|x A ) assumed we had animal data on two doses. If instead we had data on more than two doses, we would use these to first derive independent beta priors for the DLT risk on each corresponding human dose; calculate the (100t i1 )th, . . . , (100t iK )th percentiles of each beta prior; and then follow steps (i) and (ii) to find a bivariate normal approximation to the prior for θ. consistently under-predict the human DLT risk, or a mixture of (A) and (B), over the therapeutic interval where doses have a DLT risk close to the target of Γ = 0.25. We want to leverage the preclinical data to support inferences about θ when the animal data are highly predictive of human data and quickly discount them otherwise. Another consideration is that the consequence of the prior-data conflict shown in Figure 1A may be quite different to that of the conflict shown in Figure 1B . This is because leveraging preclinical data to inform dose recommendations when they under-predict the human DLT risk may lead to overdosing patients and placing them at excessive risk.
To facilitate robust borrowing of information across species, we implement Bayesian dose-escalation procedures with a robust mixture prior for θ, which is a weighted average of an informative component, taken as π 0 (θ|x A ), and a weakly informative component, denoted by m 0 (θ). Robust mixture priors have been proposed to leverage historical controls in a new clinical trial [15] and to extrapolate adult data to paediatrics [34, 35] . Denoting the prior weight attributed to the informative component by w, a mixture prior can be written as
Rather than defining m 0 (θ) as a non-informative prior, we specify it so as to place probability mass on a wide range of plausible parameter values. We define m 0 (θ) as the pdf of a bivariate normal distribution with correlation coefficient 0, setting ) is calibrated to accommodate very flat to steep dose-toxicity curves in humans. The illustrative examples and simulation study described in Sections 5 and 6 are performed defining m 0 (θ) so as to place independent priors on θ 1 and θ 2 with θ 1 ∼ N logit(Γ), 2 2 and θ 2 ∼ N (0, 1 2 ).
Leveraging animal data using a mixture prior with dynamic weights
In this section, we propose analysing data from a phase I trial using a two-component mixture prior with dynamically chosen weights. Specifically, after completion of cohort h, we use Bayes Theorem to update the prior distribution
with the trial data from cohorts 1, . . . , h to derive the posterior distribution for θ. The posterior formed by updating π 0 (θ|x A ) with human data will also be a two-component mixture [36] , where the posterior weights will reflect the relative likelihood of the human data under each component of the prior. Note that π 0 (θ|x A ) and m 0 (θ) in (7) are as defined in Section 3, and do not depend on h. The cohort-specific prior mixture weight w (h) ∈ [0, 1] measures the similarity of the animal data and human data from cohorts 1, . . . , (h − 1). Weight w (1) will best be based on expert prior opinion on the degree of similarity between the prior predictive distribution for the human dose-toxicity relationship formed from preclinical data, and the unknown human relationship. Rather than using a prior with the same prior mixture weight, say, w (1) , at each interim analysis, we revise this weight as the trial progresses. We update the prior weight to encourage faster discounting of the preclinical data in the event of a prior-data conflict, to help ensure patient safety. In the following, we develop a Bayesian decision-theoretic framework for how to select w (h) during an ongoing phase I dose-escalation trial.
Assessment of commensurability using a Bayesian decision-theoretic approach
Let Y i represent the binary DLT outcome of a new patient assigned dose d i ∈ D, such that Y i = 1 when a patient experiences a DLT, and Y i = 0 otherwise. Furthermore, letỹ i denote the realisation of Y i . The prior predictive probability mass function of Y i given the animal data is written as:
is the pdf of the marginal prior for p i , defined in (4), for i = 1, . . . , I. Before a patient is treated, we can use the prior predictive distribution (8) to derive a prediction, η i , for Y i [37] . At any point before or during the phase I trial, the same outcome is predicted for all patients administered a particular dose. After the patient's outcome is observed, we can compare Y i with η i and compute the utility of the prediction. Let U (ỹ = , η = s) denote the utility of prediction η = s for observationỹ = , which can take values u s , for , s ∈ {0, 1}. Utilities are dimensionless quantities, independent of dose, which lie between 0 and 1. Table 1 lists all possible configurations of the predicted and observed DLT outcomes, and corresponding utilities. We consider schemes setting u 00 = u 11 = 1, thus assigning correct predictions a utility of 1, and setting u 10 = 0, that is, assigning an incorrect prediction of no DLT zero utility. We explore setting u 01 = b, with 0 < b < 1, since incorrectly predicting a no DLT outcome as a DLT (unlike the reverse) will not undermine patients' safety but rather introduce unnecessary caution. Before Y i is observed, the optimal prediction for Y i based on the animal data iŝ
and we will take these optimal predictions for comparison with the observed human data.
Fouskakis and Draper [29] suggest a metric that quantifies the discrepancy between predicted and actual values needs to be defined for assessing the accuracy of a model's prediction. We now adapt this idea to develop a measure of commensurability, which we re-evaluate at each interim analysis of the phase I trial and use to dynamically choose the prior mixture weights for the new patient cohort in (7) . We measure the consistency of the preclinical and human data by the average utility of the optimal predictions derived from animal data, taking averages across a suitable dosing range. We now describe in more detail the measure of commensurability.
For h ≥ 2, suppose we are at the (h − 1)th interim analysis when cohort (h − 1) has been treated and observed. We want to look ahead to define the weight w (h) that will define the mixture prior used to analyse the human data accrued up to cohort h. Let D (h−1) ⊆ D contain all the doses that have been tested by this stage. For each d i ∈ D (h−1) , we summarise the total number of patients who have: a) received dose d i by cohort (h − 1); and b) were predicted toxicity outcomeη = ; and c) experienced outcomẽ y = s as n (h−1) i, s . We then define the predictive utility of the preclinical information per administered dose d i ∈ D (h−1) as:
where the denominator is the maximum utility that would be achieved if all predictions were correct. Clearly c (h−1) i only measures the predictive utility of the animal data based on outcomes from the first (h − 1) patient cohorts and on one dose. To measure the predictive utility of the animal data on all 'interesting' doses we define T (h−1) ⊆ D (h−1) as the set of doses administered by interim analysis (h − 1) which are not more than one dose level lower than the current posterior estimate of the target dose. Therefore, T (h−1) comprises tested doses in the neighbourhood (i.e. within one dose level) of the current MTD estimate, as well as all other tried doses which are estimated to have a DLT risk exceeding Γ. The current estimate of the MTD is based on the posterior formed by updating the mixture prior µ (h) 0 (θ|x A ) with human data from cohorts 1, . . . , h − 1. Then, we measure the commensurability of the animal and human data by averaging c
, that is,
where |T (h−1) | is the number of doses in T (h−1) . Taking averages across T (h−1) rather than D (h−1) can be thought of as an *ad-hoc* constraint, but one which we apply in case averaging over very safe doses leads to measures of κ (h−1) artificially biased upwards. To explain why this bias might arise, we note that prior to starting the trial, we usually define D to include doses thought to be very safe based on the preclinical data. At these safe doses, even if there were differences between the DLT risk predicted from animal data and the true human risk, these differences would likely be small (in absolute terms) and unlikely to manifest themselves in discrepancies between the optimal predictions and observed human DLT outcomes. Therefore, the value of c (h−1) i for these low doses would be expected to be close to 1, even in the presence of a prior-data conflict. The quantity κ (h−1) is used to determine the mixture weight shown in (7) and thus the prior that will be used to analyse data accrued up to cohort h.
Choosing an appropriate tuning parameter
When using κ (h−1) to calculate w (h) in (7), we must bear in mind that κ (h−1) will be a noisy measure of the predictive utility of the animal data, particularly in the early stages of the phase I trial when few doses have been tried and few patients have been treated. As more data accrue, the assessment of predictive utility becomes more convincing. To reflect this, rather than set w (h) = κ (h−1) , we propose discounting κ (h−1) according to a power law relationship, with
where λ (h−1) is a time-dependent tuning parameter and λ (1) , . . . , λ (H−1) ≥ 1 are a decreasing sequence of powers. We consider two approaches for defining each λ (h) . For any choice of λ (h) , a weight w (h) = 1 will be attributed to the informative prior component in (7) if preclinical data correctly predict all DLT outcomes in humans in the first (h − 1) cohorts. A simple proposal is to relate λ (h−1) to the trial information time, that is,
where N and n (h−1) are the maximum sample size and the number of patients recruited in the first (h − 1) cohorts, respectively. A similar power law function, linking the exponent with the trial information time, has been used in a different context by Thall and Wathen [38] for response adaptive randomisation schemes.
Suppose d i ∈ D is recommended for use in cohort h. We also consider defining λ (h−1) to capture how noisy our estimate of the predictive utility of the animal data for dose d i is. Letη i denote the optimal prediction from animal data for the outcome of a patient on dose d i , and H be the maximum number of cohorts planned for the phase I trial. Before cohort h is treated, both c i , we note that given a prior predictionη i = 0 (η i = 1) the predictive utility can take values of either u 00 or u 10 (u 01 or u 11 ), with probabilities Pr(Y i = 0) and Pr(Y i = 1), which can be set equal to their current posterior modal estimates. In contrast, computing the standard deviation of c (H) i is less straightforward. We can estimate it using simulation, setting P(Y i = 1) equal to the current posterior modal estimate of the DLT risk on dose d i . We then simulate the binary outcomes of patients in each future cohort h, . . . , H, assuming all future patients receive dose d i , and calculate c (H) i . We repeat this process 5,000 times and calculate the empirical standard deviation of the simulated values of c (H) i . We define λ (h−1) as:
This reflects how noisy c i , which will be calculated based on data from the (N − n (h−1) ) patients to be recruited, given the data currently accrued from cohorts 1, . . . , h − 1. This definition of λ (h−1) implicitly reflects the trial information time, since λ (h−1) is large in the early stages of the trial and converges towards 1 as the trial progresses. In Section 6, we will compare the operating characteristics of dose-escalation procedures using λ (h−1) as defined in (13) and (14) .
Design and analysis of the example trial incorporating animal data
In this section, we illustrate how our proposed approach can be used to incorporate preclinical information into a phase I dose-escalation study. Here, we define the target dose as one associated with a DLT risk of Γ = 0.25.
Prior distributions based on preclinical information
We return to the AUY922 example described in Section 2. For illustrative purposes, we suppose that 0.1 and 2.7 mg/kg have each been tested in 30 dogs, of which 1 and 17 experienced DLTs, respectively. Using allometric scaling, standardising body weight (BW) by body surface area (BSA), one can calculate the human doses equivalent to 0.1 and 2.7 mg/kg in dogs as:
where the right hand side translation factor, defined by BW and BSA, appropriate for dogs is (10/0.5), as specified in the FDA draft guideline Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers [1] . Thus, the equivalent human doses are 2 mg/m 2 (labelled as dose d −1 ) and 54 mg/m 2 (labelled as dose d 0 ), with corresponding risks of toxicity p −1 and p 0 in humans. We summarise the dog data as prior distributions p −1 ∼ Beta(1, 29) and p 0 ∼ Beta (17, 13) .
Recall that for the AUY922 phase I trial, D = {2, 4, 8, 16, 22, 28, 40, 54, 70} mg/m 2 . The human equivalent doses for our preclinical data happen to lie in D. Assuming the human dose-toxicity relationship follows Model (2), we can follow steps (i) and (ii) in Section 3 to compute the 2.5th, 50th and 97.5th percentiles of the marginal prior distributions of p 1 , . . . , p 9 and search to find a bivariate normal approximation to the prior distribution of θ|x A which is given by: Figure 2A compares the percentiles of the marginal priors with the fitted percentiles corresponding to the bivariate normal distribution defined above. From Figure 2A we see that our hypothetical data on 60 dogs suggest that doses 16 and 22 mg/m 2 have a risk of toxicity in humans close to the target level of 0.25. Figures 2B -2C summarise marginal prior distributions for p 1 , . . . , p 9 calculated based on the bivariate normal approximation to θ | x A given in (15) . Figure 2B summarises each marginal prior by three interval probabilities: (i) the probability of underdosing, said to occur when p i ∈ [0, 0.16); (ii) the probability that p i lies in the target interval [0.16, 0.33); and (iii) the probability of overdosing, said to occur when p i exceeds 0.33 [23] . Figure 2C presents the prior probability density curves for the lowest doses in D. In our illustrative example, we set dose 4 mg/m 2 as the starting dose for the phase I trial as it appears to be safe with P(p 2 < 0.1 | x A ) = 0.825.
To evaluate the effective sample size (ESS) of the marginal prior distribution for p i implied by π 0 (θ | x A ), we approximate it by a Beta(a, b) distribution with matching first and second moments. The ESS is then (a + b) [32] . Table 2 lists prior ESSs for our hypothetical example. The preclinical data provide information on the DLT risks on low doses equivalent to that which would be obtained from 16.4 -20.1 humans. This prior information may overwhelm data from a small phase I trial. Therefore, it is important to see whether our approach for dynamically leveraging animal data to learn about parameters of a dose-toxicity relationship leads to a dose-escalation procedure with sensible operating characteristics, particularly when there is a prior-data conflict. In the next Section, we use hypothetical data examples to explore the behaviour of dose-escalation procedures based on our proposed priors for θ.
Hypothetical data examples
From Figure 2B , we see that ahead of the phase I trial, doses up to 16 mg/m 2 comply with the escalation criterion defined in (1) if probabilities are based on the robust prior in (7) with h = 1 and w (1) = 1. We analyse data from the first human cohort setting w (1) = 1 because a priori we believe the starting dose determined from preclinical information is safe, meaning there would be little chance of observing a conflict between the predicted human outcome (of no DLT) and the observed human outcomes. Dynamic updating of the prior mixture weight is implemented from the first interim analysis and onwards, when accumulated human toxicity data is compared with the prior predictions obtained from animal data.
We simulated three data examples, where there is (i) a negligible prior-data conflict; (ii) a conflict that the dog data under-estimate the DLT risk in humans; and (iii) a conflict that the dog data overestimate the DLT risk in humans. Dose escalation trials follow the BLRM procedure outlined in Section 2, implemented at each interim analysis (h − 1), h = 2, . . . , H, using the mixture prior for θ, µ (h) 0 (θ | x A ), defined in Section 3 with empirical weights reflecting the predictive utility of the dog data with a tuning parameter of the form shown in (14) . Patients were recruited in cohorts of size three and each hypothetical trial can recruit a maximum of, for example, 11 cohorts. Once responses are available for all patients in each cohort h, h = 1, . . . , H, the prior is updated using Bayes Theorem based on all available human data from cohorts 1, . . . , h to obtain the posterior:
H denotes the human data from the first h cohorts and w (h) * denotes the posterior mixture weight attributed to the posterior
We fit our Bayesian model with a robust mixture prior using Markov chain Monte Carlo. The OpenBUGS [39] code for implementation is provided in Appendix C. Figure 3 presents the dosing trajectory and evolution of the prior mixture weight attributed to π 0 (θ | x A ) for the three data examples. Looking across the three hypothetical trials, we see that the first discrepancy between the human data and their prior predictions occurs in the first cohort of data example 2 and the fourth cohort of data examples 1 and 3. As noted in Section 4.1, a disagreement between predictions and observed data could take a few cohorts to emerge, even when there is a conflict between the true human dose-toxicity curve and predictions based on the animal data. The prior mixture weight on π 0 (θ | x A ) decreases immediately from the value of 1, after the first disagreement has been observed. Looking across all three data examples, the prior mixture weight typically plateaus or increases slightly over the last couple of cohorts. This is because the predictive utility measure κ (h−1) looks at the commensurability of the human and animal data, and is unlikely to vary substantially over the final stages of the trial, while the tuning parameter λ (h−1) reduces to 1 as the trial progresses.
We focus now on data examples 2 and 3, to explore how the prior mixture weights evolve in the presence of a prior-data conflict. In data example 2, the prior mixture weight that will be used to analyse data accrued from the first fourth cohorts, w (4) , increases to 0.767 after the rapid initial discounting of the preclinical information, due to correct predictions of outcomes in cohorts 2 and 3 on the two lowest doses. However, all three patients in cohort 4 administered 8 mg/m 2 experience toxicities, outcomes which the animal data wrongly predict as no DLTs. In response to this, w (5) drops to 0.083. Data example 3 shows how the procedure reacts to a data-conflict when the DLT risks in humans are much lower than predicted by the animal data. In cohorts 4 and 5 assigned 22 mg/m 2 and 28 mg/m 2 , respectively, no DLTs are observed which contradicts the prior predictions based on animal data. Consequently, the prior weights used for analysis at next interim analyses drop to w (5) = 0.533 and w (6) = 0.250. With the lower prior weight w (5) , the posterior weight w resulted in an escalation to dose 54 mg/m 2 , at which one out of three patients was observed with a DLT. A de-escalation to 40 mg/m 2 then took place, and the estimate of the target dose eventually converged at this dose level. Finally, we note that using our approach leads to a compromise between full pooling and complete discarding of preclinical animal data. Results of these assessments are available in Figure  S1 in the Web-based Supplementary Materials.
Specifying a run-in period
As was illustrated in Section 5.2, the methodology described in Sections 3 and 4 tends to implement full borrowing of preclinical information in the early stages of the phase I trial when human toxicity outcomes at low doses can be correctly predicted. However, it is counterintuitive that we should assign full weight to the preclinical data in the early stages of a trial when few human data are available to assess commensurability. This is particularly true since we know the agreement between prior predictions, based on animal data alone, and the observed human data may be an artefact of starting the trial with very safe doses rather than a reflection of a genuine agreement. If the true dose-toxicity relationship in humans has a very steep slope, placing full weight on the animal prior could lead to overly aggressive escalation decisions and unexpected DLTs.
To this end, we consider a constrained version of our approach with a run-in period. We set the prior mixture weight equal to 0 until the first discrepancy is observed in cohort h . From interim analysis (h + 1) onwards, accumulated human data are then analysed with a mixture weight calculated as described in Sections 3 and 4. Under this scheme, the dose-escalation trial begins basing interim decisions on a weakly informative prior m 0 (θ). To reach a fair conclusion about the impact of having a run-in period, we present three new data examples in Figure 4 where observations are sampled without replacement from the same simulated datasets used to create the corresponding data examples in Figure 3 . For instance, focusing on data example 1, the first patient assigned 28 mg/m 2 in Figure 3 will have the same simulated toxicity outcome as the first patient assigned 28 mg/m 2 in Figure 4 .
Implementing the run-in period has no impact on data example 2, since the first conflict between the animal predictions and the human outcomes occurred in cohort 1. For data examples 1 and 3, we notice that dose escalation decisions tend to be less conservative when using the run-in period, especially in the early stages of the simulated trials, leading to different interim dose recommendations, as shown in Figure 4 . By the end of each simulated trial implementing the constrained version of our approach, we observed the prior mixture weights w (11) are equal to the values obtained when we implement the unconstrained version. This is due to (i) our way of simulating the human toxicity data, which ensures the same likelihood of the human toxicity across our illustrative examples presented in Figures 3 and 4 , and (ii) the fact that the prior mixture weight is dynamically determined based on the compatibility of preclinical and clinical trial data.
6 Simulation study 6 
.1 Basic settings
We continue with our motivating example from Sections 2 and 5, and evaluate the operating characteristics of dose-escalation trials designed and conducted basing inferences on the mixture prior described in Sections 3 and 4 with empirical decision-theoretic weights. Comparisons are made with Bayesian procedures basing inferences on mixture priors with fixed weights. We consider:
• Procedure A: Bayesian mixture prior with dynamic decision-theoretic weights; no run-in period • Procedure C: Bayesian mixture prior with w (h) = 0.5 for all h; no run-in period
• Procedure D: Bayesian informative prior, that is, w (h) = 1 for all h; no run-in period
• Procedure E: Bayesian weakly informative prior, that is, w (h) = 0 for all h Procedures A and B are implemented using expression (14) to calculate the λ tuning parameters. We specify a fixed weight of 0.5 for Procedure C, as we speculate this will ensure the mixture prior has heavy enough tails to adequately deal with most prior-data conflicts. We use the optimal non-parametric design (O'Quigley et al., 2002) as a benchmark for comparison.
We assume the data on 60 dogs described in Section 5.1 are available prior to the phase I clinical trial. To evaluate how rapidly procedures react to a prior-data conflict, we simulate small phase I trials recruiting up to seven cohorts of three patients, with doses in D available for evaluation. As explained in Section 5.1, patients in cohort 1 are assigned the dose 4 mg/m 2 . Interim analyses are performed incorporating both animal and human toxicity information the dose for the next patient cohort is selected according to a variant of criterion (1) such that
with the same constraint on a maximum two-fold escalation in dose. Trials end either when all 21 patients have been treated and observed, or at any interim analysis h if Pr( 25 . These two subsets of simulated trials will be referred to as completed or stopped early trials, respectively. Phase I trials are simulated under the eight human toxicity scenarios shown in Table 3 . In Scenario 3, the human DLT risk on each dose is consistent with the prior median estimate obtained from the dog data, where these estimates are illustrated in Figure 2A and were derived assuming the dose-toxicity relationship in humans follows a logistic regression model. In none of the scenarios were the human DLT risks derived from a logistic regression model. For all Bayesian procedures A-E, estimates of operating characteristics are based on 1000 simulated trials per toxicity scenario.
Letp i denote the posterior median DLT risk for d i ∈ D recorded on completion of the trial. At the end of a completed trial, we declare the target dose to bê
where D c ⊆ D comprises all doses that have been administered to humans during the trial and which satisfy safety criterion (1). For each scenario, we report the percentage of simulated trials stopped early for safety without selecting a target dose, and the percentage of simulated trials which are completed declaring dose d i as the target dose, for i = 1, . . . , 9. We are particularly interested in comparing procedures A -E in terms of the percentage of early stopping in an overly toxic scenario, and the probability of correct selection (PCS) in scenarios where we expect the phase I trial will end with identification of an MTD. We also report the average number of patients allocated to each dose across the 1,000 simulated trials. Figure 5 visualises the operating characteristics of simulated phase I dose-escalation trials (using u 01 = 0.6), in which inferences were made using Procedures A -E. Comprehensive numerical results are presented in Supplementary Table S1, along with results for the case where we set u 01 = 0.2. Versions of our results using expression (13) as a tuning parameter for the weights in Procedures A and B are provided in Figure S2 of the Supplementary Materials. Figure 5 visualises the operating characteristics of simulated phase I dose-escalation trials (using u 01 = 0.6), in which inferences were made using Procedures A -E. Comprehensive numerical results are presented in Supplementary Table S1 , along with results for the case where we set u 01 = 0.2. Versions of our results using expression (13) as a tuning parameter for the weights in Procedures A and B are provided in Figure S2 of the Supplementary Materials.
Results
Focusing on procedures A and B using a mixture prior with empirical decision-theoretic weights, we can draw conclusions about the value of incorporating a run-in period. We see that Procedures A and B perform similarly in almost all scenarios except Scenario 8. In this scenario, the dog data over-predict the human DLT risk: the drug is in fact very safe in humans with the highest dose being the MTD. Procedure A, which considers leveraging animal data from the outset of the trial, thus tended to be more cautious in the early stages, with more patients treated at low, very safe, doses. The procedure is slow to discount the animal data because they predict no DLTs at low doses up to 16 mg/m 2 . In contrast, Procedure B (with a run-in period) allowed quicker escalation than Procedure A, since the animal data are only leveraged after the first disagreement between animal predictions and human outcomes has been observed. By this point, we had typically escalated up to higher doses, where the prior-data conflict was more likely to manifest itself in the observed data. This explains why, in Panel (ii), on average only 1.3 out of 21 patients were allocated to 70 mg/m 2 by Procedure A, while slightly more (2.4 out of 21) were allocated to the true MTD by Procedure B in Scenario 8. Panel (i) shows that the PCS for Procedure B in Scenario 8 is 33.8% compared with 20.3% for Procedure A. We observe that this difference is even larger if we take a smaller utility such as u 01 = 0.2. A similar line of reasoning explains differences between Procedures A and B in Scenario 6.
Procedure E selects dose 70 mg/m 2 as the MTD for 58.0% of the simulated trials in Scenario 8. This reveals a weakness of our methodology in situations where there are differences between the prior dose-toxicity relationship and the true curve in humans, but these are too small to result in discrepancies between the prior predictions and the human outcomes. Implementing our approach with a run-in period improves operating characteristics as it enables us to escalate up to higher doses where there is a greater chance of observing a disagreement between animal predictions and human responses.
Comparing Procedures B and C, we see that the former leads to an increase in PCS from 38.1% to 48.7% in Scenario 3, when the preclinical and human data are commensurate. In other scenarios, both procedures have similar operating characteristics, such as PCS and the number of patients treated with the MTD. In results not shown here, we found that in scenarios where there is a prior-data conflict, Procedure B achieves higher PCS than versions of Procedure C with fixed prior mixture weights set equal to a constant between 0.5 and 1. Comparing Procedures B, D and E, we see that Procedure B offers a compromise between incorporating the preclinical data with no down-weighting and no leveraging of animal data at all. While Procedure D achieves maximum PCS in Scenarios 2 -4 when preclinical and human data are commensurate, it performs very poorly in Scenarios 6 and 8 when there is a prior-data conflict; the situation is reversed for Procedure E. However, Procedure B maintains reasonable operating characteristics over a range of scenarios. Figure S2 of the Supplementary Materials summarises operating characteristics of Procedures A and B using expression (13) for the tuning parameter used to discount our measure of predictive utility when calculating w (h) . Results are similar to those shown here. We have also run simulations setting the maximum trial sample size as 33 (i.e., 11 patient cohorts) and 45 (i.e., 15 patients cohorts). Similar conclusions are drawn, with the exception that differences between Procedures A and B for the PCS in Scenario 8 diminish with increasing maximum trial sample size. This is because as the number of patients increases, the trial can escalate up to the highest dose when using Procedure A before the maximum sample size has been reached. On the other hand, if we had more informative animal prior, say, the variances of dose-toxicity parameters suggested by preclinical information are smaller, than those of the one currently in use for illustration, adopting Procedure B becomes more advantageous than Procedure C for its assessment of commensurability to determine the amount of information to borrow.
Discussion
The question of using historical data in a new clinical trial has been discussed elsewhere, but in the context of leveraging preclinical information into a phase I first-in-man trial, there are unique circumstances to be taken care of. Indeed, the challenge is to address potential prior-data conflicts, arising from the intrinsic difference between toxicity of a drug to animals and humans, which emerge in a sequential trial planned with a small sample size. Here, "small" is meant in relation to the prior effective sample size. In this paper, we have outlined solutions for translating preclinical animal toxicity data recorded on their original scale to make inference on the toxicity in humans, especially at the doses available to be administered to patients, and proposed a Bayesian decision-theoretic approach to using such information in an ongoing phase I dose-escalation trial in an adaptive way. Commensurability of the translated animal data with the newly accrued toxicity data is successively assessed to determine a sensible amount of borrowing. A formal measure to inform the commensurability was defined in terms of how correct the prior predictions based on animal data can be by comparing them with the observed outcomes available later on. Incorrect predictions will be penalised by giving a small utility value to quickly discount animal data during the course of a phase I clinical trial.
Illustrative examples and the simulation study show that the proposed methodology leads to sensible borrowing of preclinical information to aid decision making in a phase I clinical trial, and is responsive to a prior-data conflict emerges any time during the trial. We note robust inference does not seem to be possible in a most basic kind of borrowing based on the Bayes Theorem that incorporates preclinical information as what it is entirely. Conventionally, if desired to be used in a new phase I clinical trial, animal data would usually be down-weighted to contain least amount of information in the beginning so as to avoid overriding data from the trial. Whereas, our approach provides a possibility to borrow strength from animal data adaptively. It is a developed version of mixture prior with feasible mid-course modification of the prior mixture weight. As we have observed from the simulations comparing our approach with its origin, potential benefit includes the increased borrowing in cases of prior-data consistency and the capability of discounting any inconsistent prior even quicker.
When formulating the research problem, we have assumed that animal data were available from two interesting doses, as quite a few preclinical animal studies are conducted to evaluate the toxicity on a qualitative basis. However, this should not be taken as a restriction of applying the proposed methodology. When richer animal data are available from a number of preclinical in vivo studies performed in one species, information may be synthesised using meta-analysis to derive the prior predictive distribution for probability of toxicity per dose in humans, and used to make optimal prior predictions for assessing the commensurability of the synthesised animal data with human toxicity data. The discussion of using animal data collected from preclinical studies involving multiple animal species is beyond the scope of this paper. In such a more challenging case, we may wish to allocate larger weights to species that are more relevant to humans than others, whereas the decision-theoretic approach proposed at present does not allow us to draw the distinction. This is where we look toward for the future work to extend the methodology. We are also currently pursuing the use of animal pharmacokinetic information by establishing a Bayesian doseexposure-toxicity model in light of the increasing interest in better understanding and characterisation of dose-toxicity relationship [40, 41] .
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Because θ 1 in z j can be expressed with θ 2 and p i given the logistic regression model that
the joint prior pdf g i (p i , θ 2 ) can therefore be parameterised with only p i and θ 2 . The marginal probability density function for p j , the risk of toxicity at dose d i , i = 1, . . . , I, can then be derived by integrating out the nuisance parameter θ 2 :
B. Implied percentiles on the scale of p j , given a bivariate normal prior for θ
For log p 1−p = z, the 95% credible interval for p is bounded by
1+exp(z U ) should we have known the lower and upper limits of z. Here z can be seen as a transformed random variable, as following our
B.1. The first two moments of the transformed random variable z
The expectation for z is
. By Taylor expansion, we know
The last step follows the Taylor approximation exp(x) ≈ 1 + x, which works well for small x. Having
. Thus, the first moment for z is approximated as
Since
while we have
Thus,
For the Cov(θ 1 , exp(θ 2 )) in (20) , with Stein's Lemma, it holds that
For the Var(exp(θ 2 )) in (20) ,
B.2. The lower and upper limits of z
With (18) and (20), the lower and upper limits of z are
Obtaining the implied percentiles denoted by q jk , we can then easily code up the optimiser used to find a bivariate normal prior π(θ) given the prior probabilities q jk obtained following steps described in Section 3. 
C. OpenBUGS code for implementation

A. DATA EXAMPLES FOR NO BORROWING OR FULL POOLING OF ANIMAL DATA
In Section 5.2, we simulated three hypothetical phase I clinical trials to exemplify interim dose recommendations, using the proposed method to leverage preclinical data without undermining patients' safety. Here, we show in Figure S1 how doses would have been recommended in an alternative Bayesian dose-escalation procedure driven by either an operational prior m 0 (θ) or an animal prior π 0 (θ|x A ). These new data examples presented in Figure S1 were simulated from the same parameter settings used for those presented in Figure 3 of the main manuscript for a fair comparison: a vector of binary outcomes on each dose were simulated and then sampled without replacement as each new patient was assigned to a dose in the dose-escalation study. For example, looking at data examples with the same label, the first patient receiving dose 28 mg/m 2 in Figure 3 and Figure  S1 , involved in different Bayesian dose-escalation procedures will have the same simulated binary toxicity outcome. We may therefore observe what could have been the consequence by adopting different priors in a Bayesian dose-escalation procedure.
From this comparison, we can see the impact of leveraging the preclinical data on decision making in an adaptive phase I clinical trial. Using our approach leads to compromises between full pooling and complete discard of preclinical animal data. In the simulated trials labelled with data example 1, we observe that behaviours of the trial using our approach is similar with that implememted with Bayesian approach fully incorporating animal data in the prior, as under this prior-data consistency scenario a large prior mixture weight will be attributed to animal data based upon our assessment of commensurability. Advantages of using our approach are also evident in scenarios of a prior-data conflict: unlike a trial with animal data fully incorporated, less patients were allocated with overly toxic dose 8 mg/m 2 in data example 2, while more patients will have chance to escalate to a true target dose which is dose 40 mg/m 2 in data example 3.
B. NUMERICAL RESULTS OF ALL EVALUATE SCENARIOS
The performance of trials using BLRM-guided dose-escalation Procedures A -E are compared with that of the optimal non-parametric benchmark design by [1] . The optimal design is defined using the 'complete' toxicity profile of each patient, created by assuming there are J i clones of a patient given doses spanning the dosing set D i . A toxicity tolerance thereshold n is generated from U[0, 1] for the nth patient, which determines the corresponding toxicity outcome at the jth dose as
where 1(·) is the indicator function. An unbiased estimate for p i j is thusR j (N) = Improvements beyond this bound are not possible unless strong parametric assumptions are made about dose-response relationships. In our context, we wish to quantify the gains that can be made over the benchmark designs, in part due to borrowing strength from the preclinical data. Table S1 provides a complete listing of all simulation results for analysis models defined in Section 6 and the optimal benchmark design.
C. ADDITIONAL SIMULATION RESULTS
We present additional results in Figure S2 from the simulation study, where λ (h−1) = N/n (h−1) together with u 01 = 0.6 was used to compute the prior mixture weight w (h) attributed to the informative preclinical component in the mixture prior. Each simulated trial has maximum 21 patients; that is, in total seven cohorts. Results show that Procedures A and B stipulating the tuning parameter λ (h−1) = N/n (h−1) work equally well as their variants stipulating λ (h−1) in the form of (14) defined in the main manuscript. What has also been shown here in Figure S3 is the results from another simulation study, where we set the maximum trial sample size to be 33 (i.e., 11 patient cohorts). With increase of trial sample size, differences between Procedures A and B for the PCS in scenario 8. As was explained in the main manuscript, this is because we will have chance to escalate to the highest dose when more information accrues from the current trial to overcome the incompatible animal prior information. Sc.: Scenarios; pTox: true probability of toxicity in humans; Sel: proportion of times of declaring a dose as MTD; Pts: average number of patients allocated to a dose.
